



The future of cancer therapy

How can current EU policy initiatives pave the way towards treatment optimisation as part of health systems?

Webinar on 3 February 2021 from 15:00-17:00 CET

Agenda

Agenda	
5'	Introduction
	Peter O'Donnell
5'	Opening remarks
	MEP Dolors Montserrat – ENVI and BECA Committee
40'	The added value of treatment optimisation
	How will treatment optimisation improve relevant outcome measures and generate clinically robust precision treatments?
	Dr. Denis Lacombe – EORTC Director General A case study from the cancer field.
	Prof. Guy Brusselle – Dept. of Respiratory Medicine UZ Gent & ERS A case study from the respiratory field
60'	Roundtable discussion
	Panel discussion moderated by Peter O'Donnell with: MEP Véronique Trillet-Lenoir – ENVI and EMPL Committee (video message) MEP Alessandra Moretti – ENVI and BECA Committee Jan Geissler – CML Advocates Network and Patient Advisory Committee member Prof. Bengt Jönsson – Professor of Health Economics at SSE Dr. Denis Lacombe – EORTC Director General Prof. Guy Brusselle – Dept. of Respiratory Medicine UZ Gent & ERS
	 Key questions to address: How can treatment optimisation studies bridge the research gap between the preapproval development of medicines and their post-approval use in real-life practice? Who should be involved in performing treatment optimisation studies? Is there a role for EMA?
	 How can current and upcoming EU health and research programmes contribute? How can cross-border treatment optimisation studies be taken account of in essentially national decisions on access to health systems? What does 'patient-centric' mean in real-life practice?
5'	Closing remarks MEP Maria da Graça Carvalho – ITRE Committee
5′	Take-away messages
	Peter O'Donnell